AI to Advance Prevention, Treatment, and Equity in UK Primary Care Metadvice recently presented alongside Lancing & Sompting PCN Clinical Director Dr Shona Schofield at the “Tackling Cholesterol Together Roadshow” hosted by HeartUK and Health Innovation Kent Surrey Sussex. The case study, based on over 12 months implementation in the Ball Tree Surgery in West…
Details
Insulin: A Key Factor in the Nexus of Cardiometabolic Disease Andrew J Krentz Chief Medical Officer, Metadvice Defects of insulin secretion and/or action are central to the expanding worldwide pandemic of non-communicable cardiometabolic disorders (figure). In recent decades, large scale human overnutrition has fuelled exploding rates of obesity and type 2 diabetes. Uncommon a century…
Details
A staggering one-third of the global population may harbour metabolic dysfunction associated fatty liver disease (MAFLD). This burgeoning, obesity-related health crisis is projected to escalate, with obesity rates expected to jump from 15% in 2023 to ~25% by 2035. Metadvice stands at the forefront of this challenge, leveraging AI to empower clinicians in managing the complex web of chronic diseases, particularly where metabolic and cardiovascular disorders intersect. In this blog, we draw on new evidence to explore how Metadvice technology can address this growing disease area.
Details